The global flow cytometry market has grown steadily in recent years due to the growing demand for cell analysis tools. Flow cytometry is an analytical method used to analyze and detect cell characteristics at the single-cell level. In the past few years, there has been a rapid increase in chronic diseases, including autoimmune disease, diabetes, rheumatoid arthritis, and more. The growing incidence of diseases necessitates the development of advanced analytic tools that help to understand the disease at the cellular level and facilitate personalized drug development. Currently, researchers are using conventional flow cytometers for subjective and quantitative analysis of cells for cell line development and also for determining the immunological response. The expanding utilization of flow cytometry methods has caught the attention of key players in the market, who are developing innovative flow cytometers with high throughput capabilities, large volume handling capacity, and integration of automation software.
In fact, the flow cytometry domain has been evolving to integrate cord-cutting technologies that offer several benefits over the conventional cell analysis approach. These innovative categories of advanced flow cytometers include image, high-throughput, and microfluidic flow cytometers. It is worth noting that these advanced flow cytometers have been utilized for phenotypic screening, lead optimization, antibody screening, and multiplex compound profiling. Driven by the rising requirements and significance of innovative cytometry methods, the leading players in the flow cytometry market continue to evolve advanced solutions that facilitate research on novel drugs with accurate cell analysis. In this context, let’s take a deep dive into the leading companies that are currently driving innovation in this field.
Top 5 Flow Cytometry Market Players Driving Innovations
Flow cytometers have become integral to research, particularly drug discovery, disease diagnoses, and clinical trial processes. With increasing usage, there has been a surge in the requirement for novel cytometers that have the potential to reduce analysis time, minimize the risk of contamination, and handle large volumes of samples. In order to meet the growing requirements, the leading companies listed below are increasing their efforts to introduce future-driven automated flow cytometers.
▪ Beckman Coulter
Beckman Coulter is one of the leading players in the flow cytometers market, established in 1933. Danaher Corporation’s parent company handles the life sciences and diagnostic division. This company offers a wide range of cytometry instruments, reagents, and software that are widely used for disease diagnosis and developing treatment plans. Beckman Coulter has its own diagnostics platform that offers analytical instruments, consumables, reagents, software, and services for hospitals, clinical laboratories, and physicians to use for cell analysis, disease diagnosis, and treatment decisions.
▪ bioMerieux
bioMeriux is a prominent company in the flow cytometry market known for its innovations. The company was established in 1963 and founded in France. bioMerieux has developed technology-based flow cytometry services and in vitro diagnostics technologies. Recently, the company has become globally known for the flow cytometers used in disease diagnosis and research.
▪ Luminex
Luminex is a profound biotechnology corporation that provides various biological testing technologies, including flow cytometers. Its patented testing technologies include xTAG, MultiCode, and xMAP technology. Luminex’s R&D operations involve the creation of next-generation systems, chemicals, assays, and software. Luminex built its foothold in the flow cytometry market by offering various flow cytometry products and solutions. It provides a variety of instruments based on its xMAP technology.
▪ EMD Millipore
The firm offers solutions and assistance in biotechnology and pharmaceutical medication therapy. EMD Millipore is focusing on extending its operations in the global flow cytometry market with a portfolio of offerings that specialize in cellular analysis, proteomic, and genomic, as well as the preparation of samples, intuitive detection systems, and research reagents to improve the understanding of how cells work and diseases.
▪ Thermo Fisher Scientific
Thermo Fisher Scientific is a leading industrial stakeholder in the flow cytometry market. This company is headquartered in Massachusetts, US. It is well known for developing scientific instruments and software solutions that drive research and development of novel drugs and facilitate disease diagnosis with a higher accuracy rate. Presently, Thermo Fisher Scientific is focused on developing a high throughput cell analysis instrument that enables automatic monitoring of samples and control sampling to ensure the safety and quality of the end results.
Current Developments in the Flow Cytometry Market
With the continuous adoption of these analytical tools for research and drug development purposes, several industrial leaders enter into strategic partnerships to encourage innovation in the field. Some of the top development activities that have taken place in this flow cytometry market are listed below.
⬝ In June 2023, BD successfully launched the new BD FASCDuet™ (Premium Sample Preparation System) for various applications of flow cytometric analysis. The system utilizes liquid handling robotics to prepare samples, thereby improving reproducibility and standardization in cellular diagnostics.
⬝ In May 2023, BD Life Sciences and Sehgal Path Lab conjointly launched a Centre of Excellence for flow cytometric clinical research in Mumbai. The launch of Centre of Excellence for flow cytometry by BD Life Science in India marked as the third equipment with the company’s proprietary flow cytometers, encouraging the value of flow cytometry within clinical diagnosis.
Concluding Remarks
In conclusion, the significant increase in the interest of industrial stakeholders in the flow cytometry segment encourages the development of advanced analytical solutions to facilitate drug discovery and development. The emerging technological advances in this domain have been validated by the increasing collaboration and partnership activities between key players. Additionally, the growing requirement of high throughput screening methodologies caters to the attention of leading players to expand their existing capacities and capabilities for the development of tech-driven flow cytometers that can meet the future requirements of the pharmaceutical and healthcare sectors for disease diagnosing, drug discovery, cell line development, and treatment validation. As the flow cytometry market continues to expand with ongoing advances, it is anticipated the domain will grow at a steady rate in the future.
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.
